|
Market Closed -
Other stock markets
|
After market 14:42:30 | |||
| 4.76 EUR | -2.46% |
|
4.751 | -0.19% |
| 07-02 | Nanobiotix: The Goldman Sachs Group crosses the 5% threshold | CF |
| 06-25 | ADRs End Higher; Nanobiotix S.A. Climbs 12% | DJ |
Paris, France, January 14, 2013 - NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a French company and nanomedicine pioneer developing NanoXray, a revolutionary therapeutic approach to local cancer treatment, today announces its indicative financial agenda for 2013.
|
distributed by
|
| 1st Jan change | Capi. | |
|---|---|---|
| -28.31% | 249M | |
| +16.92% | 45.34B | |
| +42.10% | 40.42B | |
| -9.85% | 37.92B | |
| +33.19% | 31.75B | |
| -8.98% | 27.71B | |
| +12.95% | 26.52B | |
| +44.71% | 13.96B | |
| +32.55% | 12.44B | |
| -7.15% | 11.26B |
NANOBIOTIX 
By 
